Overview

A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)

Status:
Completed

Trial end date:
2021-04-20

Target enrollment:

Participant gender:

Summary

A multi-centre open-label two-arm randomised superiority clinical trial of two weeks of oral Azithromycin 500mg once daily versus usual care in adult patients presenting to secondary care with clinically-diagnosed COVID-19 but assessed as appropriate for initial ambulant (outpatient) management, in preventing progression to respiratory failure or death.

Phase:

Phase 3

Details

Lead Sponsor:

University of Oxford

Collaborator:

Pfizer

Treatments:

Azithromycin